Experimental Bowel Cancer Vaccines Hailed as “Big Advance” by Consultant

A senior consultant at a prominent cancer hospital has described personalized vaccines undergoing trials for bowel cancer patients as a “really big advance”. The medical professional at The Christie Hospital in Manchester noted that while these experimental vaccines represent a “wonderful idea,” researchers must await the conclusion of the clinical trial to ascertain their true efficacy. This treatment method entails extracting a portion of a patient’s cancerous tumor to develop a vaccine. This vaccine is engineered to stimulate the body’s immune system, preparing it to respond should the disease recur. Richard Nelson, a patient from Timperley participating in the trial, has been receiving these vaccines since September, after undergoing surgery and chemotherapy. Mr. Nelson, aged 73, who received a diagnosis of stage 3 colon cancer in November 2023, expresses optimism that the vaccine might prevent the disease from returning. His treatment included surgery in December 2023, followed by chemotherapy, and he commenced the experimental vaccine 10 months subsequent to that. Mr Nelson stated: “I’d say, if you’re offered a clinical trial, go for it.” He added: “I also think I may be able to help other people, other than myself.” He mentioned that, in contrast to the debilitating impacts of chemotherapy, the vaccine produced “flu-like side-effects,” allowing him to continue enjoying “long-distance walks and hobbies including Morris Dancing.” Patients receive the experimental vaccine after undergoing surgery to excise the tumor. Professor Mark Saunders, a consultant oncologist spearheading the clinical trial at The Christie, commented: “The vaccine is a personalised one. “It gets his body’s immune system to actually fight the cancer. Hopefully it will stop it coming back.” Professor Saunders indicated that while the vaccine is currently being tested on colon cancer patients, “you could also take the antigens from other cancers and make vaccines for other patients as well.” He characterized the vaccine trial as: “a really big advance,” but cautioned: “We have to show that it works first.” He further elaborated: “Until we reach the end of the trial and work out how many people are still alive, we won’t really know if it works – but it is a wonderful idea.” Approximately 16,000 deaths annually in the UK are attributed to bowel cancer. The German pharmaceutical firm BioNTech SE is collaborating with Genentech, a constituent of the Roche Group, in the development of this vaccine. The trial is currently enrolling patients in both the UK and the United States.